Developing Innovative Therapeutics Using a Propriety High-throughput Screening System for Novel Molecular Glues

Coltac Therapeutics has developed a disruptive, cost-effective, and highly specific method for screening, discovery, and development of molecular glues for protein degradation to help treat cancer.

Coltac utilizes a multimodal, iterative approach combining deep structural biology expertise and computational approaches to select specific E3-ligase libraries for expression in a proprietary high-throughput E.Coli-based positive selection screening system. Molecular Glue drug candidates are then discovered based on their ability to enhance binding of an E3 ligase to the target protein.

Investing partner / fund: